Understanding lung disease in rheumatoid arthritis patients
Multi-centric Prospective and Observational Study of Prevalence and Incidence of Interstitial Lung Diseases in Patients With Rheumatoid Arthritis
This study looks at how common lung disease is in people with rheumatoid arthritis in southern Belgium to help improve early diagnosis and treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Liege Academic / other |
| Locations | 1 site (Liege) |
| Trial ID | NCT06184893 on ClinicalTrials.gov |
What this trial studies
This observational study aims to determine the prevalence and incidence of interstitial lung disease in patients diagnosed with rheumatoid arthritis in southern Belgium. Over a period of two years, participants will undergo various assessments, including quality of life questionnaires, pulmonary function tests, and chest CT scans. Additionally, patients may be included in sub-cohorts focusing on biomarkers and radiomic patterns to enhance early diagnosis and management of lung disease associated with rheumatoid arthritis.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old with a confirmed diagnosis of rheumatoid arthritis.
Not a fit: Patients without a diagnosis of rheumatoid arthritis or those under 18 years old may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnosis and management of interstitial lung disease in rheumatoid arthritis patients, potentially reducing morbidity and mortality.
How similar studies have performed: While this approach is novel in its specific focus on rheumatoid arthritis-associated interstitial lung disease, similar studies have shown promise in identifying pulmonary complications in other chronic conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of rheumatoid arthritis according to the criteria of the American Society of Rheumatology * Age \> 18 years * Willing to participate in the study and sign the informed consent form (ICF) of participants or their legal authorized representative * RAIDbio subcohort : available data for one of the following analysis of biomarkers: volatile organic compounds, induced sputum or blood markers * RAIDomix : available data for high resolution computed tomography of the chest Exclusion Criteria: none
Where this trial is running
Liege
- Centre Hospitalier Universitaire de Liege — Liege, Belgium (Recruiting)
Study contacts
- Study coordinator: Julien Guiot, PhD
- Email: j.guiot@chuliege.be
- Phone: 00324/323 7881
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.